A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

HIV Infections

Interventions

BIOLOGICAL

HIV-1 Peptide Vaccine, Microparticulate Monovalent

BIOLOGICAL

rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine

Trial Locations (1)

Univ of California at San Francisco Gen Hosp, San Francisco

All Listed Sponsors

lead

United Biomedical

INDUSTRY